Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Repeat Doses of BAY 1817080 in Healthy Males & Proof of Concept in Chronic Cough Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03310645
Recruitment Status : Completed
First Posted : October 16, 2017
Last Update Posted : January 26, 2023
Sponsor:
Information provided by (Responsible Party):
Bayer

Brief Summary:

To investigate the safety and tolerability of ascending repeated oral doses of BAY1817080 in healthy volunteers(Part1).

To investigate the safety, tolerability and efficacy of BAY1817080 in patients with refractory chronic cough(Part2).


Condition or disease Intervention/treatment Phase
Cough Drug: BAY1817080 Drug: Matching Placebo Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 87 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Part 1: Ascending multiple doses in healthy volunteers Part 2: Ascending doses within two-way crossover design in patients
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: double blind
Primary Purpose: Treatment
Official Title: Two-part, Double-blind, Placebo-controlled, Randomized, Parallel-group Study: (Part 1) in Healthy Male Volunteers to Assess Safety and Tolerability of Ascending Repeated Oral Doses of BAY1817080, Followed by (Part 2), Two-way Crossover Administration of Four Different Doses in Patients With Refractory Chronic Cough to Assess Safety, Tolerability and Efficacy for Proof of Concept
Actual Study Start Date : December 7, 2017
Actual Primary Completion Date : May 28, 2019
Actual Study Completion Date : June 19, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cough

Arm Intervention/treatment
Experimental: Dose 1 of BAY1817080

Study Part 1:

Oral dose 1 of BAY1817080 twice daily with a loading dose administered three times on Day 1

Drug: BAY1817080
4 different doses over the course of study

Experimental: Dose 2 of BAY1817080

Study Part 1:

Oral dose 2 of BAY1817080 twice daily with a loading dose administered three times on Day 1

Drug: BAY1817080
4 different doses over the course of study

Experimental: Dose 3 of BAY1817080

Study Part 1:

Oral dose 3 of BAY1817080 twice daily with a loading dose administered three times on Day 1

Drug: BAY1817080
4 different doses over the course of study

Experimental: Dose 4 of BAY1817080

Study Part 1:

Oral dose 4 of BAY1817080 twice daily with a loading dose administered three times on Day 1

Drug: BAY1817080
4 different doses over the course of study

Placebo Comparator: Placebo

Study Part 1:

Oral dose of matching placebo twice daily with a loading dose administered three times on Day 1

Drug: Matching Placebo
Matching placebo for BAY1817080

Experimental: Placebo+BAY1817080

Study Part 2:

Randomized crossover design in cough patients Placebo+4 different doses of BAY1817080

Drug: BAY1817080
4 different doses over the course of study

Drug: Matching Placebo
Matching placebo for BAY1817080

Experimental: BAY1817080+Placebo

Study Part 2:

Randomized crossover design in cough patients 4 different doses of BAY1817080+Placebo

Drug: BAY1817080
4 different doses over the course of study

Drug: Matching Placebo
Matching placebo for BAY1817080




Primary Outcome Measures :
  1. Frequency of treatment emergent adverse events in study part 1 [ Time Frame: Up to 5 weeks ]
  2. Severity of treatment emergent adverse events in study 1 [ Time Frame: Up to 5 weeks ]

    The intensity of an AE is classified according to the following categories:

    • Mild: A type of adverse event that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living.
    • Moderate: A type of adverse event that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant.
    • Severe: A type of adverse event that requires intensive therapeutic intervention. The event interrupts usual activities of daily living, or significantly affects clinical status

  3. Frequency of treatment emergent adverse events in study part 2 [ Time Frame: Up to 12 weeks ]
  4. Severity of treatment emergent adverse events in study part 2 [ Time Frame: Up to 12 weeks ]

    The intensity of an AE is classified according to the following categories:

    • Mild: A type of adverse event that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living.
    • Moderate: A type of adverse event that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant.
    • Severe: A type of adverse event that requires intensive therapeutic intervention. The event interrupts usual activities of daily living, or significantly affects clinical status

  5. 24-hour cough counts [ Time Frame: At week 1 in period A ]
  6. 24 hour cough counts [ Time Frame: At week 2 in period A ]
  7. 24 hour cough counts [ Time Frame: At week 3 in period A ]
  8. 24 hour cough counts [ Time Frame: At week 1 in period B ]
  9. 24 hour cough counts [ Time Frame: At week 2 in period B ]
  10. 24 hour cough counts [ Time Frame: At week 3 in period B ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Part 1

  • Male; healthy according to complete medical history, including the physical examination, vital signs (blood pressure, pulse rate), 12 lead ECG, clinical laboratory tests
  • Age: 18-45 years (inclusive) at the first screening visit.
  • Non-smoker for at least the past 6 months and with a pack year history of equal to or less than 5 years.
  • Subjects who are sexually active and have not been surgically sterilized must agree to use two reliable and acceptable methods of contraception simultaneously when having sexual intercourse with women of childbearing potential (one method used by the subject and one method used by the partner) during the study and for 90 days after receiving the investigational medicinal product and not to act as sperm donor for 90 days after dosing. [Acceptable methods of contraception include for example: (a) condoms (male or female) with or without a spermicidal agent, (b) diaphragm or cervical cap with spermicide, (c) intrauterine device, (d) hormone-based contraception.

Part 2:

  • Age: >18 years at the first screening visit
  • Refractory chronic cough for at least one year:

    • that has been shown to be unresponsive to at least 8 weeks of targeted treatment for identified underlying triggers including reflux disease, asthma and post-nasal drip or unexplained cough, and
    • for which no objective evidence of an underlying trigger can be determined after investigation.
  • Score of >40 mm on the Cough Severity visual analogue scale (VAS) at screening.
  • For male patients:

Male patients who are sexually active and have not been surgically sterilized must agree to use two reliable and acceptable methods of contraception simultaneously (one method used by the study patient and one method used by the partner) during the study and for 90 days after receiving the investigational medicinal product and not to act as sperm donor for 90 days after dosing. [Acceptable methods of contraception include for example: (a) condoms (male or female) with or without a spermicidal agent, (b) diaphragm or cervical cap with spermicide, (c) intrauterine device, (d) hormone-based contraception.

--For female patients: Confirmed post-menopausal woman (defined as exhibiting spontaneous amenorrhea for at least 12 months before screening or as exhibiting spontaneous amenorrhea for 6 months before screening with documented serum follicle-stimulating hormone (FSH) levels > 40 mIU/mL) or Woman without childbearing potential based on surgical treatment at least 6 weeks before screening such as bilateral tubal ligation, bilateral oophorectomy with or without hysterectomy (documented by medical report verification) or Woman of childbearing potential that agrees to use two reliable and acceptable methods of contraception simultaneously (one method used by the study patient and one method used by the partner) during the study and for at least 10 days after the last dose. Acceptable methods of contraception include for example: (a)condoms (male or female) with or without a spermicidal agent (b)diaphragm or cervical cap with spermicide (c) intrauterine device (d)hormone-based contraception.

Exclusion Criteria:

Part 1

  • Relevant diseases potentially interfering with the study's aims (e.g.respiratory diseases) within the four weeks before screening or between screening and randomization
  • Any febrile illness within the four weeks before screening or between screening and randomization
  • Medical history of hypogeusia/dysgeusia or the subject has a dysfunction in his/her ability to taste, as revealed by the taste disturbance questionnaire during screening and the pre dose procedures
  • Use of any over-the-counter cough mixture within the 24 hours before screening

Part 2:

  • FEV1 or FVC of less than 60% of predicted normal, at screening
  • History of upper or lower respiratory tract infection or recent significant change in pulmonary status within the 4 weeks before baseline visit.
  • Current smoking habit or history of smoking within the 6 months before the screening visit.
  • History of smoking (at any time) for more than 20 pack-years in total (20 cigarettes per pack)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03310645


Locations
Layout table for location information
United Kingdom
North Tyneside General Hospital
North Shields, Tyne And Wear, United Kingdom, NE29 8NH
Birmingham Heartlands Hospital
Birmingham, West Midlands, United Kingdom, B9 5SS
Queen's University
Belfast, United Kingdom, BT9 7AB
Castle Hill Hospital
Cottingham, United Kingdom, HU16 5JQ
King's College Hospital - NHS Foundation Trust
London, United Kingdom, SE5 9RS
University Hospital of South Manchester
Manchester, United Kingdom, M23 9LT
Medicines Evaluation Unit
Manchester, United Kingdom, M23 9QZ
Sponsors and Collaborators
Bayer
Investigators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT03310645    
Other Study ID Numbers: 18184
2017-001620-22 ( EudraCT Number )
First Posted: October 16, 2017    Key Record Dates
Last Update Posted: January 26, 2023
Last Verified: January 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: There are no current plans to share data. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bayer:
Refractory chronic cough
healthy volunteers
Additional relevant MeSH terms:
Layout table for MeSH terms
Cough
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory